Neurological
Landau-Kleffner Syndrome
Also known as LKS, acquired epileptic aphasia, verbal auditory agnosia, continuous spike-waves during slow sleep (CSWS)
Landau-Kleffner syndrome is a rare epileptic encephalopathy characterized by acquired verbal auditory agnosia (inability to understand spoken language) in children who had previously normal language development, associated with EEG abnormal
0
studies recruiting now
as of 7 Sept 2026
3
studies registered in total
as of 7 Sept 2026
0
countries with a recruiting site
as of 7 Sept 2026
None
recruiting study posted to date
among recruiting studies
Recruiting trials
No recruiting trial found right now.
3 studies are registered for Landau-Kleffner Syndrome, but none was recruiting as of 7 Sept 2026. Here is what is still worth doing.
Keep watching
Get an email when a new Landau-Kleffner Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Landau-Kleffner Syndrome
Landau-Kleffner syndrome is a rare epileptic encephalopathy characterized by acquired verbal auditory agnosia (inability to understand spoken language) in children who had previously normal language development, associated with EEG abnormalities showing continuous spike-wave activity during slow-wave sleep (CSWS). Seizures are present in most but not all patients. The language regression may be partial or complete, and outcome is variable. Treatment with corticosteroids, IVIG, and antiseizure medications may partially restore language.
Common clinical features
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Landau-Kleffner Syndrome. Not eligibility rules; those are set by each study.
- Prolonged overnight EEG documenting CSWS pattern is required for diagnosis and trial enrollment
- Formal speech-language assessment documenting receptive language regression from normal baseline is required
- Corticosteroid treatment history (response, duration, dosing) must be documented as it affects subsequent trial eligibility
- Age at LKS onset and time from language regression to treatment affects language outcome and trial stratification
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).